CA3217697A1 - Therapeutic method for cat with chronic kidney disease - Google Patents
Therapeutic method for cat with chronic kidney disease Download PDFInfo
- Publication number
- CA3217697A1 CA3217697A1 CA3217697A CA3217697A CA3217697A1 CA 3217697 A1 CA3217697 A1 CA 3217697A1 CA 3217697 A CA3217697 A CA 3217697A CA 3217697 A CA3217697 A CA 3217697A CA 3217697 A1 CA3217697 A1 CA 3217697A1
- Authority
- CA
- Canada
- Prior art keywords
- bps
- stage
- cats
- kidney disease
- ckd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021100475 | 2021-06-16 | ||
| JP2021-100475 | 2021-06-16 | ||
| PCT/JP2022/023876 WO2022265031A1 (ja) | 2021-06-16 | 2022-06-15 | 慢性腎臓病のネコの治療方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3217697A1 true CA3217697A1 (en) | 2022-12-22 |
Family
ID=84527566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3217697A Pending CA3217697A1 (en) | 2021-06-16 | 2022-06-15 | Therapeutic method for cat with chronic kidney disease |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12097177B2 (https=) |
| EP (1) | EP4356908B1 (https=) |
| JP (1) | JP7318818B2 (https=) |
| KR (1) | KR20240021749A (https=) |
| CN (1) | CN117396197A (https=) |
| AU (1) | AU2022294552A1 (https=) |
| BR (1) | BR112023023965A2 (https=) |
| CA (1) | CA3217697A1 (https=) |
| ES (1) | ES3054744T3 (https=) |
| MX (1) | MX2023013545A (https=) |
| WO (1) | WO2022265031A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025501556A (ja) * | 2021-12-27 | 2025-01-22 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 慢性腎臓病を診断及び治療するための組成物及び方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58124778A (ja) | 1982-01-20 | 1983-07-25 | Toray Ind Inc | ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体 |
| JPH075582B2 (ja) | 1986-01-24 | 1995-01-25 | 東レ株式会社 | ２，５，６，７−テトラノル−４，８−インタ−ｍ−フエニレンＰＧＩ▲下２▼誘導体 |
| JPH0662599B2 (ja) | 1987-10-16 | 1994-08-17 | 東レ株式会社 | ２，５，６，７―テトラノル―４，８―インタ―ｍ―フェニレンＰＧＩ２誘導体ならびにその製造法および用途 |
| CA2012081C (en) | 1989-03-14 | 2000-08-29 | Shigeki Itou | 2,5,6,7-tetranor-4,8-inter-m-phenylene pgi 2 derivatives |
| WO1998041210A1 (en) | 1997-03-14 | 1998-09-24 | Toray Industries, Inc. | Sustained-release prostaglandin i derivative preparation |
| ES2272914T3 (es) | 2003-05-20 | 2007-05-01 | Ethypharm | Composicion farmaceutica oral de liberacion sostenida. |
| CN101217960B (zh) | 2005-07-08 | 2010-12-15 | 东丽株式会社 | 用于改善尿毒症的治疗药和处置方法 |
| JPWO2016031949A1 (ja) | 2014-08-28 | 2017-06-22 | 東レ株式会社 | 慢性腎不全の治療薬 |
| CA3164676A1 (en) | 2019-12-23 | 2021-07-01 | Toray Industries, Inc. | Drug for preventing dialysis shift or renal death |
-
2022
- 2022-06-15 CN CN202280038404.2A patent/CN117396197A/zh active Pending
- 2022-06-15 MX MX2023013545A patent/MX2023013545A/es unknown
- 2022-06-15 US US18/565,161 patent/US12097177B2/en active Active
- 2022-06-15 CA CA3217697A patent/CA3217697A1/en active Pending
- 2022-06-15 JP JP2022542656A patent/JP7318818B2/ja active Active
- 2022-06-15 AU AU2022294552A patent/AU2022294552A1/en active Pending
- 2022-06-15 WO PCT/JP2022/023876 patent/WO2022265031A1/ja not_active Ceased
- 2022-06-15 EP EP22825019.7A patent/EP4356908B1/en active Active
- 2022-06-15 KR KR1020237035492A patent/KR20240021749A/ko active Pending
- 2022-06-15 ES ES22825019T patent/ES3054744T3/es active Active
- 2022-06-15 BR BR112023023965A patent/BR112023023965A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023013545A (es) | 2023-11-29 |
| EP4356908A4 (en) | 2024-10-23 |
| US12097177B2 (en) | 2024-09-24 |
| WO2022265031A1 (ja) | 2022-12-22 |
| EP4356908A1 (en) | 2024-04-24 |
| JP7318818B2 (ja) | 2023-08-01 |
| AU2022294552A1 (en) | 2023-11-02 |
| CN117396197A (zh) | 2024-01-12 |
| JPWO2022265031A1 (https=) | 2022-12-22 |
| US20240207218A1 (en) | 2024-06-27 |
| BR112023023965A2 (pt) | 2024-01-30 |
| EP4356908C0 (en) | 2025-10-22 |
| ES3054744T3 (en) | 2026-02-05 |
| KR20240021749A (ko) | 2024-02-19 |
| EP4356908B1 (en) | 2025-10-22 |
| TW202317089A (zh) | 2023-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7402907B2 (ja) | ネコの全身性疾患の予防又は治療用アンジオテンシンｉｉ受容体拮抗薬 | |
| US12097177B2 (en) | Therapeutic method for cat with chronic kidney disease | |
| RU2576511C2 (ru) | Пероральная терапия недостаточности витамина в12 | |
| US12502356B2 (en) | Use of higher doses of modified release huperzine formulations | |
| Jepson et al. | Management of chronic kidney disease | |
| KR101848122B1 (ko) | 환자 부분모집단에서의 통풍 치료 방법 | |
| TWI867128B (zh) | 前列腺環素衍生物用於製造用以抑制轉入透析或腎死之藥劑之用途 | |
| JP5018478B2 (ja) | 尿毒症改善のための治療剤および処置方法 | |
| Abe et al. | Efficacy of pioglitazone on type 2 diabetic patients with hemodialysis | |
| US20190321326A1 (en) | Method of treating hyperglycemia | |
| CN101115483A (zh) | 含有FBPase抑制剂的药物组合物 | |
| RU2778313C2 (ru) | Лекарственная композиция, включающая ингибитор sglt-2 и блокатор рецептора ангиотензина | |
| HK1111620A (en) | Pharmaceutical composition containing ppar gamma agonist | |
| AU2016206292A1 (en) | A method of improving liver function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250506 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250506 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260324 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260324 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260324 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260325 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260326 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260326 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260408 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260408 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260408 |